Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://thenewpainkillerconolidin02186.articlesblogger.com/60113911/conolidin-to-replace-traditional-painkillers-options